A model for screening and diagnosing abdominal tumors using CT scans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a screening and diagnostic model for abdominal tumors utilizing both non-contrast and contrast-enhanced abdominal CT scans. The study will include patients with pathologically diagnosed abdominal tumors and a non-tumor population to validate the model's accuracy. The secondary objective is to develop a grading model based on clinical indicators, enhancing the understanding and detection of abdominal neoplasms. The study will also ensure comprehensive follow-up data is collected for all participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with abdominal tumors:
* all patients were pathologically diagnosed with abdominal tumors;
* The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
* All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
* Non-tumor population:
* all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.

Exclusion Criteria:

* Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;

Where it's running

• Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
  Hangzhou, Zhejiang, China Recruiting
• Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Xiangdong Cheng — Zhejiang Cancer Hospital
• Study coordinator: Xiangdong Cheng
• Email: Chengxd516@126.com
• Phone: 0086-571-881280

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intravenous contrast-enhanced ultrasound for diagnosing children's abdominal problems in China

  This project will try intravenous contrast-enhanced ultrasound in children (29 days–18 years) with abdominal tumors, injuries, or unexplained fluid to see if it gives clearer diagnoses.

  Recruiting The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07113808

• Treatment with STAR0602 for advanced solid tumors

  This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.

  Recruiting at 16 sites Phase 1/2 Marengo Therapeutics, Inc. · Sacramento, California and 18 other locations · NCT05592626

• Me capegfilgrastim to help prevent neutropenia in advanced breast cancer patients on chemotherapy

  This real-world registry tests whether mecapegfilgrastim used with chemotherapy helps prevent low white blood cells in adults with advanced breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07899099

• Pucotenlimab and Anlotinib with Chemo Before Surgery for Early-Stage Triple-Negative Breast Cancer

  This study tests a combo of pucotenlimab, anlotinib, and nab-paclitaxel before surgery in adults with newly diagnosed, stage II-III triple-negative breast cancer that is PD-L1 known.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou · NCT07896668

• Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites

  This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07855640

• Carbon ion lattice radiotherapy for large thoracic tumors

  This study tests a carbon ion lattice radiotherapy approach, after induction chemoimmunotherapy, in adults with unresectable locally advanced NSCLC or other thoracic solid tumors.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07744074

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.